Emvision Medical Devices Ltd. · ASX:EMV
Emvision Medical Devices — ASX Small and Mid-Cap Conference (September 2023)
19 slides from Emvision Medical Devices's conference presentation, Sep 20, 2023
Slide 1: ASX Small and Mid-Cap Conference Investor Presentation
www.emvision.com.au ASX:EMV For personal use only ASX SMALL AND MID-CAP CONFERENCE INVESTOR PRESENTATION Portable brain imaging, anywhere, anytime SEPTEMBER 2023
Slide 2: Disclaimer
DISCLAIMER For personal use only This presentation has been prepared by EMVision Medical Devices Limited (“EMVision” or “the Company”). This presentation is not a financial product or investment advice or recommendation, offer or invitation by any person or to any person to sell or purchase securiti
Slide 3: Overview: EMVision is an innovative medical device company
OVERVIEW EMVision is an innovative medical device company For personal use only developing world first electromagnetic portable brain scanner products to address significant unmet clinical needs. Originally spun out of the University of Queensland. Founded in 2017 Experienced team “Zero to one” afte
Slide 4: The Team
THE TEAM SIGNIFICANT MEDICAL DEVICE DEVELOPMENT AND GLOBAL COMMERCIALISATION EXPERTISE ACROSS THE GROUP Executive leadership team Board of Directors For personal use only Scott Kirkland John Keep As former CEO of Queensland Diagnostic Imaging, Sales and marketing executive, former Head of CEO and Ma
Slide 5: EMVision is creating world first portable brain scanners
EMVISION IS CREATING WORLD For personal use only FIRST PORTABLE Neuroimaging as is BRAIN SCANNERS accessible today. EMVision, Neuroimaging anywhere. 1st Gen 2nd Gen www.emvision.com.au 5
Slide 6: Bringing imaging to where stroke occurs will save lives
BRINGING IMAGING TO TRADITIONAL IMAGING TOOLS WHERE STROKE OCCURS • Mainstay imaging techniques, CT and MRI, produce excellent images but are for the most part large, stationary and For personal use only WILL SAVE LIVES complex machines that require specialist operators, limiting their point-of-care
Slide 7: Overview of 1st Gen and 2nd Gen clinical value
OVERVIEW OF 1ST GEN AND 2ND GEN CLINICAL VALUE UNMET NEED FOR PRE-HOSPITAL AND BEDSIDE IMAGING ACROSS THE ENTIRE PATIENT JOURNEY A typical stroke patient journey & timeline in an urban setting For personal use only 15 mins to 2.5hrs <2.5 hours <3 hours <24 hours <24 hours 3 weeks <3 weeks 3 years +
Slide 8: Point-of-care brain imaging, anywhere, anytime
POINT-OF-CARE BRAIN IMAGING, ANYWHERE, ANYTIME For personal use only “This is an exciting development in stroke and neurological care. We have found the EMVision scanner to be a very user-friendly portable imaging modality. The Device demonstration video (https://youtu.be/BYtjYcJvoVs) EMVision scann
Slide 9: Innovating at pace: proof-of-principle study
INNOVATING AT PACE IMAGING EXAMPLES PROOF-OF-PRINCIPLE STUDY • Safe, portable, fast, cost effective and easy to use imaging modality • IP portfolio spans software, hardware and multiple indications For personal use only • EMVision’s unique technology has been published in: Patient examples from proo
Slide 10: Positive market feedback; health economic assessment
POSITIVE MARKET FEEDBACK ENCOURAGING HEALTH ECONOMIC ASSESSMENT US primary market research supports proposed Estimated Gen 1 potential financial benefits to a public purchasing models hospital in Australia¹ For personal use only • 20 US based stroke specialists, with involvement in Reduction in $120
Slide 11: US reimbursement strategy
MS-DRG Description Medicare Total Examples Payment Charges US REIMBURSEMENT STRATEGY USD USD 061 Ischaemic stroke w/ $20k $118k thrombolysis + major complications Approximately 75% of stroke cases in the United States are covered by Centers 066 Haemorrhagic stroke $5k $43k For personal use only w/o
Slide 12: US market respondent feedback on 1st Gen device
US MARKET RESPONDENT FEEDBACK ON 1ST GEN DEVICE Commentary from stroke care respondents on use cases in a tertiary hospital setting, remote areas and anticipated scan volumes For personal use only Will be used much more often POC for remote areas with accessibility limitations We do way more than 5
Slide 13: More lives could be saved with our 2nd Gen solution
MORE LIVES COULD BE SAVED WITH • Mobile Stroke Units (MSU) essentially bring the stroke unit to the patient, providing faster diagnosis and treatment, improving disability OUR SCALABLE AND LIGHTWEIGHT outcomes 2nd GEN BRAIN IMAGING SOLUTION • However, the model is resource intensive (including radio
Slide 14: Pathway to market entry
PATHWAY TO MARKET ENTRY (GEN 1 DURING FY25) For personal use only GEN 1 Notified Body Conformity EU Multi-site clinical trials Assessment (CE Marking) Pre-validation phase – Objectives: hardware verification, usability, safety, data for AI models 3 key sites activated (Liverpool, Royal Melbourne and
Slide 15: Attractive revenue models and total addressable market
ATTRACTIVE REVENUE MODELS TOTAL ADDRESSABLE MARKET Traditional capex or innovative opex selling model offerings to provide buyer flexibility. Direct or distributor sales channels. For personal use only CAPITAL EQUIPMENT & MONTHLY 1st GEN ADDRESSABLE MARKET - ~$15Bn CONSUMABLES MODEL SUBSCRIPTION MOD
Slide 16: Partners & collaborators
PARTNERS & COLLABORATORS TRACK RECORD OF SECURING AND ONGOING ACCESS TO NON-DILUTIVE FUNDING PROVIDES GOOD FLEXIBILITY GRANT SCHEMES ARE COMPETITIVE AND SUBJECT TO DUE DILIGENCE BEFORE AWARD For personal use only Clinical Research Partnership Commonwealth CRC-P Grant Program Collaborators Access to
Slide 17: Set up for success; key upcoming catalysts
SET UP FOR SUCCESS KEY UPCOMING CATALYSTS For personal use only • We have assembled a team of medtech experts that • Generate positive pre-validation and validation have successfully done this before and created clinical trial data, achieving recruitment objectives significant shareholder value and
Slide 18: Capital structure
CAPITAL STRUCTURE ASX TICKER: EMV • Secured ~$20m in non-dilutive funding since inception For personal use only Headquarters: • $4.4m ongoing non-dilutive staged grant funding available 4.01, 65 Epping Road, Macquarie Park • Modest historical cash burn Sydney, Australia • Multi-centre clinical trial
Slide 19: Thank you
THANK YOU For personal use only EMVISION WEBSITE EMAIL OFFICES ASX:EMV emvisionmedical.com skirkland@emvision.com.au 4.01, 65 Epping Road, Macquarie Park Sydney, Australia Translational Research Institute, 37 Kent Street, Woolloongabba Queensland, Australia
EMVision Medical Devices — ASX Small and Mid-Cap Conference (September 2023) on 6ix